Searchable abstracts of presentations at key conferences in endocrinology

ea0081p49 | Calcium and Bone | ECE2022

Extended treatment with recombinant human parathyroid hormone (1-84) in adult patients with chronic hypoparathyroidism: a phase 4 study

Rubin Mishaela , Cusano Natalie , Yin Shaoming , Tokareva Elena , Ayodele Olulade , Finkelman Richard D.

In Europe, rhPTH(1-84) is an approved adjunctive treatment for adults with chronic hypoparathyroidism that cannot be adequately controlled with conventional therapy. Here we present data from the longest rhPTH(1-84)-treated study cohort of patients with hypoparathyroidism. In a single-centre, single-arm, phase 4 study (NCT02910466), long-term rhPTH(1-84) treatment (25, 50, 75, or 100 μg/day subcutaneously) was evaluated in adults with chronic hypoparathyroidism who mainta...